Arovella Therapeutics Ltd
ALA
Company Profile
Business description
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Contact
84 Hotham Street
Corporate One
PrestonVIC3072
AUST: +61 398636472
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
44
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,175.10 | 49.90 | 0.61% |
| CAC 40 | 7,502.78 | 20.42 | 0.27% |
| DAX 40 | 22,064.51 | 102.54 | 0.47% |
| Dow JONES (US) | 40,093.40 | 486.83 | 1.23% |
| FTSE 100 | 8,407.44 | 4.26 | 0.05% |
| HKSE | 22,133.04 | 223.28 | 1.02% |
| NASDAQ | 17,166.04 | 457.99 | 2.74% |
| Nikkei 225 | 35,681.78 | 642.63 | 1.83% |
| NZX 50 Index | 12,017.84 | 61.37 | 0.51% |
| S&P 500 | 5,484.77 | 108.91 | 2.03% |
| S&P/ASX 200 | 7,968.20 | 47.70 | 0.60% |
| SSE Composite Index | 3,298.40 | 1.11 | 0.03% |